Clinical Trials Directory

A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered TG101348 in Patients With Primary, Post-polycythemia Vera, or Post-essential Thrombocythemia Myelofibrosis

The purpose of this study is to evaluate the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : TG101348

Phase: Phase 1


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia) - At least 18 years of age. - ECOG PS 0, 1, or 2.

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrea Linder
Not Recruiting

Footer Links: